Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Catalent | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Catalent

Drug Delivery Segment up 10% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent
 
1Q Revenues: $442.2 million (+5%)

1Q Earnings: $4.6 million (earnings were $11.7 million 1Q16)

Comments: Revenue from the Softgel Technologies segment was $186.4 million, an increase of 1%. Revenue from the Drug Delivery Solutions segment was $191.3 million, up 10% primarily driven by volumes related to fee-for-service development and analytical testing in the U.S., the company’s biologics offering and European pre-filled syringe operations. This growth was partially offset by decreased volume in integrated oral solids development and manufacturing capabilities. Revenue from the Clinical Supply Services segment was $75.0 million, down 3%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters